SynthesisFrontiers in immunology2026
Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibody-based therapies have become a cornerstone of Ebola virus disease (EVD) treatment and prevention, particularly following the successful clinical development of monoclonal antibody therapeutics against Zaire ebolavirus. However, despite substantial advances, the global research landscape, collaboration patterns, and evolving thematic trends of Ebola antibody therapy have not been systematically characterized. The ongoing 2026 Bundibugyo ebolavirus outbreak, for which no licensed vaccines or therapeutics currently exist, further underscores the importance of understanding the development trajectory of this field. Methods: Publications related to antibody therapy for EVD published between 1990 and 2026 were retrieved from the Web of Science Core Collection, PubMed, and Scopus databases. Following data integration, format conversion, and deduplication, a total of 1,350 unique publications were included. Bibliometric analyses were conducted using CiteSpace, VOSviewer, and Bibliometrix, complemented by Google Trends data to evaluate public interest and outbreak-related attention. Results: The field exhibited dynamic outbreak-driven growth, with major publication surges corresponding to the 2014-2016 West African Ebola epidemic and the period surrounding 2020. Although annual publication output declined after 2020, renewed public attention emerged during the 2026 Bundibugyo outbreak. The United States dominated both publication productivity and citation impact, followed by China, the United Kingdom, and Canada. Harvard University, the University of Texas System, and Scripps Research Institute were identified as leading institutions. Keyword co-occurrence and clustering analyses revealed five major thematic domains: fundamental virology and glycoprotein research, immunity and vaccination, infection and therapeutic development, cross-viral research involving COVID-19 and HIV, and clinically oriented studies focused on neutralizing antibodies, clinical trials, and convalescent plasma. Temporal analyses demonstrated a clear evolution from basic virology toward translational and clinical applications. Conclusions: Ebola antibody therapy research has undergone substantial expansion over the past three decades, driven largely by major outbreak events and advances in antibody engineering technologies. The current Bundibugyo outbreak highlights persistent vulnerabilities in existing countermeasure strategies and emphasizes the urgent need for broadly protective pan-ebolavirus antibody therapeutics. These findings provide a comprehensive overview of the intellectual structure, global collaborations, research hotspots, and future directions of antibody-based interventions against Ebola virus disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.